ARTICLE | Clinical News
FDA grants Regeneron's evinacumab breakthrough therapy designation for HoFH
May 12, 2017 5:39 AM UTC
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA granted breakthrough therapy designation to evinacumab (REGN1500) to treat homozygous familial hypercholesterolemia (HoFH). The mAb targeting ang...
BCIQ Company Profiles
BCIQ Target Profiles